

Feasibility First: Early Assessments of Your Drug Candidate Using Mechanistic Modeling

Evaluate your R&D challenges and the potential success of your drug candidate at early stages.

Early feasibility assessment (EFA) is the application of mechanistic PKPD modeling using data readily available early in the R&D process. EFA empowers teams to evaluate the potential success and challenges of a drug candidate at early stages, make effective dose predictions, and discover optimal ranges for your drug and target parameters.

Maximize ROI with informed decision-making

This quantitative and methodical approach helps teams in early discovery determine if a therapeutic enters the portfolio, and what experiments are most important moving forward early on in a project.



EFA Enables Increased Confidence in Decision-Making

Guide your drug development with precision and confidence

- Optimize therapeutic window by identifying optimal drug and target properties to fit desired dosing regimens
- Streamline experiments by exploring the sensitivity of various drug or target parameters
- Quickly compare multiple 'what-if' scenarios to determine the impact of different dosing regimens or drug designs



Impact

- Prioritize early R&D experiments and optimize experimental designs
- Advance promising preclinical candidates

EFA Enables Resource Efficiency

- Allocate resources based on informed predictions



Impact

- Terminate infeasible projects early on
- Open up resources and costs for promising projects

EFA Enables Accelerated Timelines

- Capture market opportunities swiftly by bringing therapies to patients sooner



Impact

- Compress timelines by minimizing rounds of lead generation
- Save from 1-4 years of lost opportunity in time
- Increase your competitive edge with a faster response to market needs

Explore EFA with Applied BioMath Assess™

EFA can be incorporated into every drug discovery and development program, and **Applied BioMath Assess™**, a web-based application that provides the necessary models and analyses via an intuitive interface, makes this integration a reality.

Applied BioMath Assess™ is a point-and-click, model-informed drug discovery and development (MID3) software to assess efficacy, safety, and therapeutic index for early stage biotherapeutics.



Trial for free or request a demo

Use Applied BioMath's Early Feasibility Assessment Tool:
Applied BioMath Assess™



Try a 7-Day Free Trial: Use our pre-built models to test it out yourself – No modeling experience needed!

Request a Demo: Our support team will walk you through an early feasibility assessment demo.

